Iron and Physical Performance: The Everyday Female Athlete’s Power Mineral

Why Iron Matters for Performance Oxygen Transport and Energy Production Iron is a key component of hemoglobin and myoglobin, ...

Argenx outlines five registrational readouts in 2026 while expanding VYVGART global reach

The introduction of five upcoming registrational readouts for 2026 is a new forward-looking highlight. Product net sales and operating profit both increased meaningfully quarter-over-quarter, as did ...

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

The third quarter 2025 financial results and business update will be discussed during a conference call and webcast presentation today at 1:30 pm CET/8:30 am ET. A webcast of the live call and replay ...

Nutritionist Reveals 5 Times Women Might Want To Skip Their Coffee

Coffee is a staple for many, but according to nutritionist Lovneet Batra, there are certain situations when women should ...
Pharmabiz

Merck & Eisai announce Welireg plus Lenvima meets primary endpoint of PFS in certain previously treated patients with advanced RCC

Merck & Eisai announce Welireg plus Lenvima meets primary endpoint of PFS in certain previously treated patients with advanced RCC: Rahway, New Jersey Wednesday, October 29, 2025, ...
Pharmabiz

Merck & Eisai’s phase 3 LEAP-012 trial of Keytruda plus Lenvima in unresectable, non-metastatic HCC fails to achieve statistical significance for overall survival

In combination with pembrolizumab, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). In combination with everolimus, for the treatment of adult patients with ...
Le Lézard

Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus

Bristol Myers Squibb today announced Week 52 data from the pivotal Phase 3 POETYK PsA-1 trial further confirming the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic ...
Opinion

What will happen if the FDA really bans natural thyroid?

On August 7, 2025, the Food and Drug Administration announced that it would be demanding the elimination of natural thyroid treatment, otherwise known as desiccated thyroid extract (DTE) or natural ...

Argenx rises after Q3 earnings beat on strong sales growth

Investing.com -- Argenx (EBR: ARGX) shares climbed more than 2% on Thursday after the Belgian biopharmaceutical company reported third-quarter results that exceeded forecasts, led by stronger product ...

Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Pa…

Merck and Eisai Announce WELIREG® Plus LENVIMA® Met Primary Endpoint of PFS in Certain Previously Treated Patients With ...

Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell R…

Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma ...
Healthline

Can Hyperthyroidism Cause Weight Gain?

Hyperthyroidism (overactive thyroid) doesn’t usually cause weight gain, though it may cause other weight changes. Sometimes, treatment for hyperthyroidism can lead to weight gain. Hyperthyroidism ...